Abstract:Recently, anti PD-1/PD-L1 immunotherapies have yielded promising outcomes in advanced squamous NSCLC. Several studies have suggested that tumor PD-L1 protein expression status might correlate with outcome and response to treatment. The aim of this study is to identify mRNA gene signatures and microRNAs associated with tumor PD-L1 expression in early-stage lung squamous cell carcinoma (SCC). Early stage (I-II) SCC resected patient tumors were collected from 6 cancer centers as part of the SPECS II program. Gene expression profiling was performed on the specimens. PD-L1 protein expression was evaluated by immunohistochemistry on SCC FFPE tissue using the Dako 22C3 PD-L1 antibody. The tumor proportion score (TPS) for PD-L1 protein expression was compared with comprehensive clinicopathological, mRNA and miRNA data. The prevalence of PD-L1 expression in this cohort of 255 Stage I-II SCC patients was 46.7% with a TPS cutoff of ≥ 1%, and 9.8% with a cutoff of ≥50%. Among 202 cases with available clinical and expression data, no significant association was observed between PD-L1 expression and clinical outcome. We identified a 12-gene signature from mRNA microarray using the Minimax Concave Penalty (MCP) regression method with an AUC of 0.92 at ≥ 5% TPS cutoff. A subset of 138 miRNAs was shown to be significantly differentially expressed between PD-L1 positive and PD-L1 negative groups at false discovery rate (FDR) of 0.05 with TPS cutoffs of ≥1%, ≥5% and ≥10%. No miRNAs were found to be significantly differentially expressed between the groups using a TPS cutoff of ≥50%. Gene Set Enrichment Analysis (GSEA) identified two pathways with gene sets that were significantly enriched (FDR <0.05) in the PD-L1 negative group. No significant association was found between tumor mutation burden and PD-L1 expression level. PD-L1 expression prevalence is lower in early-stage lung SCC than in advanced NSCLC. No significant association was found between PD-L1 expression and prognosis in this cohort. Both mRNA gene signatures and miRNAs were identified to be predictive of PD-L1 expression. Through GSEA, two distinct gene sets were identified with expression correlated to PD-L1, one comprising genes related to ovary and another related to collagens and extracellular matrix (ECM). No significant association was found between tumor mutation burden and PD-L1 expression level. Following validation, these predictive signatures could be used to select patients with positive PD-L1 expression who may benefit from immunotherapy.

MP73-17 RAB20, AIM2, AND BCL2A1 INHIBIT PENILE SQUAMOUS CELL CARCINOMA CELL PROLIFERATION

Molecular Characterization of Clinically Defined Aggressive Variant Prostate Cancer (avpca) in Prospectively Collected Tissues and Corresponding Patient Derived Xenografts (PDX).

Identification of Key Genes and Evaluation of Clinical Outcomes in Lung Squamous Cell Carcinoma Using Integrated Bioinformatics Analysis

Proteomic and Phosphoproteomic Maps of Lung Squamous Cell Carcinoma from Chinese Patients.

Prognostic Gene Signature for Squamous Cell Carcinoma with a Higher Risk for Treatment Failure and Accelerated MEK-ERK Pathway Activity

Molecular characterization and integrative genomic analysis of a panel of newly established penile cancer cell lines

Identification of a Methylation Panel Aid in Risk Stratification in Node‐positive Penile Squamous Cell Carcinoma

Effective combinatorial immunotherapy for penile squamous cell carcinoma

Gene Expression Profiling of the Peritumoral Immune Cell Infiltrate of Penile Squamous Cell Carcinomas

Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort

Mutational Landscape of Penile Squamous Cell Carcinoma in a Chinese Population

Kinase analysis of penile squamous cell carcinoma on multiple platforms to identify potential therapeutic targets

A panel of cancer testis antigens in pan squamous cell carcinomas: implication for biomarkers and therapeutic targets

Imbalanced Expression of Mitogen-Activated Protein Kinase Phosphatase-1 and Phosphorylated Extracellular Signal-Regulated Kinases in Lung Squamous Cell Carcinoma

Machine Learning Analysis of PD-L1 and CD8 Expression Patterns in Penile Squamous Cell Carcinoma: Implications for Immunotherapy

MA 13.02 Comprehensive Genetic Analysis Related to PD-L1 Expression in Early-stage Lung Squamous Cell Carcinoma

miR-138-5p-mediated HOXD11 promotes cell invasion and metastasis by activating the FN1/MMP2/MMP9 pathway and predicts poor prognosis in penile squamous cell carcinoma

The prognostic significance of p53, Ki-67, epithelial cadherin and matrix metalloproteinase-9 in penile squamous cell carcinoma treated with surgery.

Molecular characterization of metastatic penile squamous cell carcinoma in developing countries and its impact on clinical outcomes: LACOG 2018 translational study

Development and Validation of a DNA Methylation Panel for the Prediction of Outcome in Node-Positive Penile Squamous Cell Carcinoma after Lymphadenectomy.

Immunophenotypes Based on the Tumor Immune Microenvironment Allow for Unsupervised Penile Cancer Patient Stratification